Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL	Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Leukemia, Lymphocytic, Acute, L2, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 1	2026-08-26		NCT05495035

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Institute of Hematology & Blood Diseases Hospital, China	285

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Department of Hematology/Oncology, Shanghai Jiaotong University School of Medicine Affiliated Shanghai Children's Medical Center	Shanghai	China	1
Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences	Tianjin	China	2
Qilu Hospital of Shandong University	Jinan	China	68
The Second Affiliated Hospital of Anhui Medical University	Hefei	China	20